Back to today’s briefing

Story perspectives

UK Biotech AviadoBio Targets Frontotemporal Dementia with Gene Therapy

6/14/2025

41 5

Summary

Story summary

AviadoBio, a pioneering biotech company from the UK, is on a mission to tackle frontotemporal dementia (FTD), a condition impacting 20,000-40,000 individuals in the UK. Their innovative gene therapy focuses on the GRN gene mutation, striving to rejuvenate brain cell function. With clinical trials in progress across several countries, hope is on the horizon as initial results are anticipated next year, promising a new dawn for FTD treatment.

1 of 1

Story summary

AviadoBio, a pioneering biotech company from the UK, is on a mission to tackle frontotemporal dementia (FTD), a condition impacting 20,000-40,000 individuals in the UK. Their innovative gene therapy focuses on the GRN gene mutation, striving to rejuvenate brain cell function. With clinical trials in progress across several countries, hope is on the horizon as initial results are anticipated next year, promising a new dawn for FTD treatment.